Fund Details
Revelation Partners
Overview
Investment portfolio
27rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Aspen Neuroscience | Nov 2025Led | $115 MSeries C | |
VitalConnect | Feb 2025Participated | $100 MOther Equity | |
Nouscom | Mar 2024Participated | $8 MSeries C | |
SPR Therapeutics | Feb 2024Led | $85 MDebt | |
VitalConnect | Jul 2023Led | $30 MSeries F | |
Carrum Health | May 2023Participated | $45 MSeries B | |
Vedanta Biosciences | Apr 2023Participated | $107 MOther Equity | |
Syapse | Jul 2022Participated | $35 MOther Equity | |
Dren Bio | Jun 2022Participated | $65 MSeries B | |
Aspen Neuroscience | May 2022Led | $148 MSeries B | |
IntelyCare | Apr 2022Participated | $115 MSeries C | |
Gravie | Mar 2022Participated | $75 MSeries E | |
Aspen Neuroscience | Nov 2025Led | $115 MSeries C | |
VitalConnect | Feb 2025Participated | $100 MOther Equity | |
Nouscom | Mar 2024Participated | $8 MSeries C | |
SPR Therapeutics | Feb 2024Led | $85 MDebt | |
VitalConnect | Jul 2023Led | $30 MSeries F | |
Carrum Health | May 2023Participated | $45 MSeries B | |
Vedanta Biosciences | Apr 2023Participated | $107 MOther Equity | |
Syapse | Jul 2022Participated | $35 MOther Equity | |
Dren Bio | Jun 2022Participated | $65 MSeries B | |
Aspen Neuroscience | May 2022Led | $148 MSeries B | |
IntelyCare | Apr 2022Participated | $115 MSeries C | |
Gravie | Mar 2022Participated | $75 MSeries E |
27 Items
27
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series B | 1 | 5 |
| Series C+ | 3 | 9 |
| Other Equity | 2 | 5 |
| Debt | 1 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 2 |
| Jun '20 | 0 |
| Jul '20 | 2 |
| Aug '20 | 1 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 1 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 2 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 2 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 1 |
| Apr '22 | 1 |
| May '22 | 1 |
| Jun '22 | 1 |
| Jul '22 | 1 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 1 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 26 |
| Enterprise Software | 5 |
| Space & Frontier Tech | 5 |
| Hardware & Robotics | 4 |
| Data, Analytics & IT | 4 |
| Fintech | 3 |
| Professional Services | 3 |
| Manufacturing | 1 |
| Real Estate & Construction | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 1 |
| $25M-$50M | 10 |
| $50M-$100M | 8 |
| $100M-$250M | 7 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 26 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Kaiser Permanente Ventures | 4 |
| Ally Bridge Group | 3 |
| Amgen Ventures | 3 |
| Casdin Capital | 3 |
| OrbiMed | 3 |
| Perceptive Advisors | 3 |
| Section 32 | 3 |
| Accelmed | 2 |
| Alexandria Venture Investments | 2 |
| ARCH Venture Partners | 2 |
| Avestria Ventures | 2 |
| AXA Venture Partners | 2 |
| B Capital Group | 2 |
| Canaan Partners | 2 |
| Dreamers VC | 2 |
| Echo Health Ventures | 2 |
| EQT Life Sciences (LSP) | 2 |
| Essex Woodlands | 2 |
| FirstMark Capital | 2 |
| Fiscus Ventures | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 7 | 26% |
| Participating | 20 | 74% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 5 | 71% |
| Co-led | 2 | 29% |
Team
Doug Fisher
Partner and Liz Staley, Chief Compliance Officer
Mike Boggs
Director
Scott Halsted
Managing Partner